Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ImmuCell Corporation (ICCC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.48-0.28 (-3.61%)
At close: 04:00PM EDT
Advertisement

ImmuCell Corporation

56 Evergreen Drive
Portland, ME 04103
United States
207 878 2770
https://immucell.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees64

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael F. BrighamPres, CEO, Principal Financial Officer, Treasurer, Sec. & Director359.59kN/A1961
Ms. Bobbi Jo BrockmannVP of Sales & Marketing and Director299.58kN/A1977
Ms. Elizabeth L. WilliamsVP of Manufacturing Operations265.12kN/A1956
Elizabeth S. ToothakerDirector of Fin. & Admin.N/AN/AN/A
Mr. A. Gustavo ScaffaSr. Director of QualityN/AN/AN/A
John W. ZinckgrafDirector of Product Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Corporate Governance

ImmuCell Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement